Hanmi Pharm "Labstreeple shows direct efficacy in improving liver fibrosis targeting NASH"

Hanmi Pharm announced on the 23rd that it participated in the European Association for the Study of the Liver (EASL) held in Vienna, Austria from the 21st to the 24th (local time) and presented two research results on 'LAPSTrip agonist (LAPSTrip)', an innovative new drug under development for the treatment of non-alcoholic steatohepatitis (NASH).

Exterior view of Hanmi Pharmaceutical headquarters. [Photo by Hanmi Pharmaceutical]

The research presented by Hanmi Pharm this time evaluated the efficacy of directly improving 'liver fibrosis', one of the key indicators in NASH treatment. Hanmi Pharm explained that although various therapeutic candidates are currently in clinical development stages, they have not shown clear effects in improving liver fibrosis.

LAPSTrip is a triple-acting biopharmaceutical that activates glucagon-like peptide (GLP)-1 receptor, glucagon receptor, and GIP receptor all at once. Based on its multi-pharmacological effects, it is expected to effectively improve complex symptoms of NASH patients such as fatty liver, liver inflammation, and liver fibrosis.

At this conference, Hanmi Pharm presented research results that reproducibly confirmed the direct liver inflammation and liver fibrosis improvement efficacy of LAPSTrip in various liver fibrosis animal models without accompanying fatty liver. Additionally, when comparing the effects of LAPSTrip with various incretin analogs (GLP-1, GLP-1/GIP), it was proven that LAPSTrip showed differentiated efficacy in improving liver fibrosis compared to other incretin analogs.

Hanmi Pharm is currently conducting a late-phase clinical phase 2 trial in the United States and Korea to confirm the therapeutic efficacy, safety, and tolerability of LAPSTrip compared to placebo in NASH patients with fibrosis confirmed by liver biopsy.

A Hanmi Pharm official stated, "LAPSTrip agonist, which acts directly on the liver, shows superior liver fibrosis improvement efficacy compared to other candidates," and added, "We will focus the company's research and development (R&D) capabilities on developing LAPSTrip to become a 'game changer' in the NASH field, where a global market worth 30 trillion won is expected to form in the future."

Notice regarding the presentation content of 'EASL Congress 2023' posted on Hanmi Pharmaceutical's English website.
[Image provided by Hanmi Pharmaceutical]

This content was produced with the assistance of AI translation services.